Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03728842|
Recruitment Status : Recruiting
First Posted : November 2, 2018
Last Update Posted : March 4, 2021
|Condition or disease||Intervention/treatment|
|Melanoma; Renal Cell Carcinoma||Other: Blood collection for laboratory studies Other: Data collection from medical record|
Spontaneous regression in patients with metastatic cancer is an incredibly rare event. It has been described after infection in cancer patients and also rarely in patients with renal cell cancer (usually after resection of the renal primary) and, less commonly, in patients with metastatic melanoma.
Primary Objective To collect peripheral blood from patients with metastatic melanoma and renal cell cancer and spontaneous regression for studies of immune response and other studies.
Secondary Objective To collect clinical data from subjects registered to this study. Clinical data collection will include demographics and cancer characteristics, history and treatment.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Blood Drawing for Study of Peripheral Blood T-lymphocytes and Other Parameters in Patients With Metastatic Melanoma and Renal Cell Cancer With Spontaneous Regression|
|Actual Study Start Date :||February 24, 2003|
|Estimated Primary Completion Date :||March 1, 2021|
|Estimated Study Completion Date :||March 1, 2021|
Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
Other: Blood collection for laboratory studies
Peripheral whole blood will be collected
Other: Data collection from medical record
Clinical data such as demographics and cancer characteristics, history and treatment will be collected
- Number of blood samples collected [ Time Frame: 1 year ]samples collected from metastatic melanoma and renal cell cancer patients
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03728842
|Contact: Theodore Logan, MDfirstname.lastname@example.org|
|United States, Indiana|
|Indiana University Simon Cancer Center||Recruiting|
|Indianapolis, Indiana, United States, 46202|
|Contact: Sheila Dropcho, RN 317-278-4191 email@example.com|
|Principal Investigator: Theodore Logan, MD|
|Principal Investigator:||Theodore Logan, MD||Indiana University School of Medicine|